Oncology Clinical Trials in Beverly Hills, CA
As of July 2026, 37 paid clinical trials are recruiting for Oncology in Beverly Hills, California. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Beverly Hills
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
38 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
A Study of PHST001 in Advanced Solid Tumors
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
About research studies in Beverly Hills
Beverly Hills has approximately 157 recruiting research studies across a wide range of therapeutic areas. California hosts a dense network of world-class research institutions, including UC San Diego Health, Stanford Medicine, UCLA Health, UCSF, City of Hope, and Scripps Research. The state's thriving biotech corridor and diverse patient population make it a national hub for both early-phase and late-phase clinical research.
Top Research Study Locations in Beverly Hills
Researchers run research studies in Beverly Hills, CA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Tower Cancer Research Foundation | Anatomic Stage II Breast Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 24 |
| Beverly Hills Cancer Center | Metastatic Breast Cancer, Breast Cancer, Non Small Cell Lung Cancer | 15 |
| National Heart Institute | Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure, Aortic Stenosis | 14 |
| Retina-Vitreous Associates Medical Group | Geographic Atrophy, Diabetic Macular Edema, AMD | 11 |
| Cedars-Sinai Medical Center | Obesity or Overweight, ATTR Amyloidosis Wild Type, ATTR Gene Mutation | 8 |
| Precision NextGen Oncology | Advanced Cancer, Brain Metastases, Adult, Cervical Cancer | 4 |
| Precision NextGen Oncology & Research Center | Advanced Solid Tumors, CNS Tumor, Cancer | 4 |
| Precision NextGen Oncology and Research Center | Adenocarcinoma of Lung, Advanced Lung Cancer, Carcinoma, Non-Small-Cell Lung | 4 |
| Cardiovascular Research Foundation of Southern California | ASCVD, ASCVD Management, Atherosclerosis | 3 |
| Cedars-Sinai Cancer Beverly Hills | Breast Cancer, Breast Cancer Metastatic, Breast Neoplasm | 3 |
| Retina Vitreous Associates Medical Group | Age-related Macular Degeneration (AMD), DME, Diabetic Macular Edema | 3 |
| Cardiovascular Res Found | Aortic Stenosis, Cardiovascular Disease and Lipoprotein(a) | 2 |
| Cedars-Sinai Cancer at Beverly Hills (THO) | Carcinoma, Lung Cancer, Non Small Cell Lung Cancer | 2 |
| Clinical Trial Site | High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension | 2 |
| Pacific Oaks Medical Group | HIV Infections, Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | 2 |
| R3 Anti Aging Beverly Hills | Low Back Pain, Osteoarthritis, Knee | 2 |
| UCLA Health Beverly Hills Primary & Specialty Care | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | 2 |
| Wallace Rheumatic Study Center | Primary Sjogren's Disease, Systemic Lupus Erythematosus (SLE) | 2 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| ADARx Clinical Site | Geographic Atrophy Secondary to Age-related Macular Degeneration | 1 |
| Adverum Clinical | Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | 1 |
| Amicis Research Center - Beverly Hills | Difficult to Control Hypertension | 1 |
| Amicis Research: Beverly Hills | Diabetes Mellitus, Type 2, Metabolic Syndrome, PreDiabetes | 1 |
| Attune Health Research Inc | Telemedicine | 1 |
| Attune Health Research, Inc | Active Idiopathic Inflammatory Myopathy, Antisynthetase Syndrome, Dermatomyositis | 1 |
Active & Upcoming Studies in Beverly Hills (2026)
Recruiting trials in Beverly Hills grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (68 active studies)
- Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer · Phase 2 · Yuan Yuan
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) · Phase 3 · Bristol-Myers Squibb
Eye & vision (14 active studies)
- A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study · Phase 3 · YS Life Science Co., Ltd.
- Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration · Phase 1, Phase 2 · Eyconis INC.
Cardiovascular (12 active studies)
- A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study · Phase 3 · YS Life Science Co., Ltd.
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
Diabetes & metabolic (6 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease · Phase 3 · Boehringer Ingelheim
Neurology & pain (2 active studies)
HIV / STI (1 active study)
Common conditions studied in Beverly Hills
- Anatomic Stage II Breast Cancer AJCC v8 (6 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Breast Cancer (6 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Non Small Cell Lung Cancer (5 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Geographic Atrophy (4 active studies). Recruiting Geographic Atrophy studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Metastatic Breast Cancer (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Systemic Lupus Erythematosus (4 active studies). Lupus trials explore B-cell and interferon-targeted therapies, CAR-T approaches, and new immunosuppressants for systemic disease.
Leading research sponsors in Beverly Hills
- AstraZeneca
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- AbbVie
- Alliance for Clinical Trials in Oncology
Local regulations and guidelines
Clinical trials in California are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. In addition, California-specific protections such as the California Consumer Privacy Act (CCPA) and the Confidentiality of Medical Information Act (CMIA) impose stringent data-privacy requirements on research involving California residents.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Beverly Hills. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Beverly Hills
Hipa.ai aggregates every recruiting study in Beverly Hills from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Beverly Hills?
There are approximately 157 recruiting clinical trials in Beverly Hills, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Beverly Hills pay participants?
Most recruiting trials in Beverly Hills compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Beverly Hills?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Beverly Hills?
The most common conditions under active study in Beverly Hills include Anatomic Stage II Breast Cancer AJCC v8 (6), Breast Cancer (6), Non Small Cell Lung Cancer (5), Geographic Atrophy (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Beverly Hills?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Beverly Hills on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Beverly Hills?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Beverly Hills?
Recruiting research sites in Beverly Hills include Tower Cancer Research Foundation, Beverly Hills Cancer Center, National Heart Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Beverly Hills right now?
The largest active categories in Beverly Hills are Cancer & tumors (68), Eye & vision (14), Cardiovascular (12). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.